Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for movie industry professionals · Friday, March 29, 2024 · 699,614,649 Articles · 3+ Million Readers

IntelGenx to Report Fourth Quarter and Full-Year 2017 Financial Results on March 29, 2018 – Conference Call to Follow

SAINT LAURENT, Quebec, March 23, 2018 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX VENTURE:IGX) (OTCQX:IGXT) today announced that it will release its fourth quarter and full year 2017 financial results after market close on March 29, 2018.

An accompanying conference call will be hosted by Dr. Horst G. Zerbe, President and Chief Executive Officer, and Mr. Andre Godin, Executive Vice-President and Chief Financial Officer, to discuss the results and provide a business update. Details of the conference call and webcast are below:

Date: Thursday, March 29, 2018

Time: 4:30 p.m. EDT

Conference dial-in: (833) 211-3233

International dial-in: (647) 689-3955

Conference ID: 6786519

Webcast Registration: Click here

Following the live call, a replay will be available on the Company's website, www.intelgenx.com, under "Investor Relations."

About IntelGenx:

Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform.

IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to its clients. More information about the company can be found at www.intelgenx.com.

Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release.  Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Source:  IntelGenx Technologies Corp.

For more information, please contact:
                    
                    Stephen Kilmer
                    Investor Relations 
                    (514) 331-7440 ext 232
                    stephen@intelgenx.com
                    
                    Or
                    
                    Andre Godin, CPA, CA
                    Executive Vice-President and CFO
                    IntelGenx Corp.
                    (514) 331-7440 ext 203
                    andre@intelgenx.com

Primary Logo

Powered by EIN News


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release